Focus on the Year To Date Gainers: $IMVT $KALA $WIX

The Market Signal was created as a platform to help investors, if you own (NASDAQ:IMVT), (NASDAQ:KALA) or (NASDAQ:WIX) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

https://themarketsignal.com/Free-Report/NOW
(Click link above or copy, paste and hit enter in your browser for your report)

Immunovant provides details on recent study

https://themarketsignal.com/Free-Report/IMVT

(Click link above or copy, paste and hit enter in your browser for your report)

The year to date stock of Immunovant Inc. (NASDAQ:IMVT) scaled higher by a 134.15% margin. This company is impressed about the topline results emanating from its ASCEND MG study. The company focussed on the study to help pati9emnts struggling with myasthenia gravis (MG).

The placebo-controlled trial sought to evaluate aspects such as pharmacodynamics, tolerability, safety and efficacy of IMVT-1401.The patients in focus are those experiencing the moderate-to-severe generalized MG. It was a treatment spanning about six weeks, and it comprised of three arms. Those were the placebo (N=5), 680 mg IMVT-1401 weekly (N=5), and 340 mg IMVT-1401 weekly (N=5).

Reports showed the IMVT-1401-treated patients as having witnessed major positive changes. The changes were checked out in the MGC scale, in which case there was an 8.0 points improvement.

Kala Pharmaceuticals take on EYSUVIS

https://themarketsignal.com/Free-Report/KALA

(Click link above or copy, paste and hit enter in your browser for your report)

The year to date performance of Kala Pharmaceuticals Inc. (NASDAQ:KALA) rose by a margin of 122.76%.

Second Quarter and Recent Highlights:

Kala has spoken in relation to EYSUVIS. The company had reached out to the Food and Drug Administration (FDA), wanting it to do something about the New Drug Application (NDA) resubmission for the product. The body outlined that the resubmission had been completed appropriately.

Upon approval, Kala will proceed to commercialize its product within the United States. If all goes well, it may soon be increasing the number of its specialty sales force. The number may reach up to 100 to 125 sales representatives. They will be entrusted with the promotion of INVELTYS and EYSUVIS.

The start of March 2020 was a challenging time. That is considering how much the INVELTYS prescriptions got affected by the prevailing COVID-19 outbreak and effects. For instance, there were restrictions by the federal, state and local governments. Those were restrictions focusing on the elective procedures and part of those were the ocular surgeries. The INVELTYS prescriptions are said to be growing over the second quarter. In the week ended April 17th , they rose from 544 to 3,000.

Wix.Com speaks on effe4cts of COVID-19 to its business

https://themarketsignal.com/Free-Report/WIX

(Click link above or copy, paste and hit enter in your browser for your report)

The year to date performance of Wix.Com Ltd. (NASDAQ:WIX) rose by a margin of 121.65%. This company has experienced increased revenues over the second quarter. The business also speaks about a loss incurred, which it closely attributes to meeting up the demands of customers over the in the course of the COVID-19 outbreak. The COVID-19 restrictions and lockdowns impacted its business adversely, but it will be shifting its focus to the online platforms in the hope things might improve.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

comtex tracking

COMTEX_370979999/2705/2020-09-09T06:26:37

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.